Beda Pharmaceuticals intends to issue H shares and apply for listing on the main board of the Hong Kong Stock Exchange

On January 7, Beda Pharmaceuticals announced that its board of directors had considered and approved the company's issuance of foreign-listed foreign shares (H-shares) and applied for listing on the main board of the Stock Exchange of Hong Kong Limited; The date decided by the person and/or the entrusted underwriter (or his representative) shall be determined to issue H-shares to foreign investors who meet the relevant conditions and to qualified domestic investors who are entitled to invest in overseas securities in accordance with the terms and conditions contained in the H-share prospecto.
announcement, the company will select the appropriate time and issue window to complete the listing within the validity period of the resolution of the shareholders' meeting.
intends to use all of the funds raised from the issuance of foreign-listed foreign shares (H-shares) after deducting the issuance costs for the Company, and may include, but not limited to, current and future domestic and overseas drug research and development, domestic and foreign commercial cooperation (including the introduction of new products through licensing), commercial sales and academic promotion, upgrading of production facilities, working capital and general enterprise use.
。